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ABSTRACT : We monitored follicular development by ultrasonography on 40 
anovulatory women on the day when we switched from HMG to HCG, and measured 
the maximum follicular diameter (mFD) and the sum total of follicular cross sectional 
area (FA) and examined the correlations of both mFD and FA with ovulation or OHSS. 
The ovulatory rate with mFD of more than 18mm was 100%. The correlation coefficients 
between mFD and serum estradiol level and moreover, FA and estradiol level were 0.3817 
and 0.8099, respectively. From the above results, it is concluded taht in order to induce 
ovulation without the hazard of causing OHSS, it is best to switch from HMG to hCG 
when the patients have FA less than 7.0cm and mFD more than 18mm, respectively.
       INTRODUCTION 
 HMG agent sometimes causes multiple preg-
nancy and ovarian hyperstimulation syndrome 
(OHSS) as its stimulation to the ovaries is 
strong. The proper preventative has not yet 
been established against multiple pregnancy, 
but as for the prevention of OHSS, at least, a 
rapid assay" Z' of estrogen in urine and serum 
to prevent the occurrence of severe OHSS has 
been developed. However, this method is not 
easy for clinical practice because it is time-
consuming and complicated. The use of ul-
trasonography (USG) has spread lately and 
monitoring of follicular development with USG 
has been carried out extensively. However, the 
usefulness of USG as a method of prevention 
of side-effects from HMG-HCG therapy has not 
yet been examined sufficiently. 
 We monitored follicular development during
HMG-HCG therapy by USG and examined the 
relationship among maximum follicular diame-
ter (mFD), total of cross sectional area of all fol-
licles (FA) and OHSS. Moreover, we tried to 
establish the criteria for predicting the occur-
rence of side effects by USG.
   MATERIALS AND METHODS 
 We gave HMG-HCG therapy to 4 women with 
anovulatory cycles (12 cycles), 12 with 1st grade 
amenorrhea (26 cycles) and 24 with 2nd grade 
amenorrhea (50 cycles), total of 40 women (88 
cycles). We gave 75-300 IU Pergonalx (HMG) 
per day, 10 times as a rule, and on the next day 
5,000 IU HCG, 1-3 times every other day. We 
started monitoring of the follicular develop-
ment after we gave the 5th or 6th dose of HMG, 
using USG (Aloka Fansonic 190 sector scan) and 
measured the maximum follicular diameter 
(mFD) which was taken from both ovaries (when
the follicle was elliptical,we measured the long 
axis), and the sum total of the cross sectional 
area of all follicles (FA) on an echogram in-
cluding each largest follicle in the bilateral 
ovaries (Fig. 1). 
 Further, the cross sectinal area of each fol-
licle was measured by the formula for the el-
liptic area, scab/4 (a: long axis, b : short axis). 
We practically calculated FA with a pocket 
computer. Also, we started gathering blood 
from the time FD became 12--13mm. After 
dividing it into serum and freezing it, we 
measured estradiol and progesterone en block 
by radioimmunoassay. Ovulation was judged 
by BBT, USG, progesterone and so on. We also 
examined the relation of mFD and FA with 
estradiol, as well as the relation between each 
parameter and ovulation or OHSS, and we tried 
to establish criteria for predicting the occurrence 
of side-effects by using USG. 
 The criteria for OHSS is established as fol-
lows : Moderate OHSS when the long axis of the 
ovary is more than 5cm, severe OHSS when it's 
more than 10cm, measured at the time when the 
ovary is most swollen, whether any other 
symptoms are present or not
          RESULTS 
1. The relation between the level of serum es-
tradiol and ovulation or OHSS. 
 In 76 out of 88 cycles in which HMG-HCG 
therapy was carried out, ovulation was succes-
sfully induced. The serum estradiol levels were 
144-2,700 pg/ml at the time of switching to HCG 
in these ovulatory cases. On the other hand, 
the levels were 56-292 pg/ml in the non-ovulatory 
cases. Furthermore, among the OHSS cases, the 
range of the serum estradiol levels for moderate 
OHSS was 577-2,400 pg/ml, while that of severe 
OHSS was 820-2,700 pg/ml. The serum estradiol 
levels of 8 cases which became pregnant were 
532-2,700 pg/ml (Fig. 2). 
2. Maximum follicular diamiter (mFD) 
 1) Correlation with serum estradiol 
 We tried to find the correlation between mFD 
 and serum estradiol levels for 88 cycles in
Fig. 1. Follicular echogram of bilateral ovaries 
       visualized in amenorrheic woman on HMG 
       administration. The cross sectional area of 
      all follicles in bilateral ovaries measured by
      the formula, nab/4 (a: long axis, b : short
       axis), was 8.8cm.
Fig. 2. The relation between the serum estradiol 
      levels and ovulation or OHSS in 88 cycles 
      (• OHSS, O* severe OHSS f pregnancy).
Fig. 3. Graph showing linear correlation between maximum follicular diameter and serum es-
      tradiol levels on the day switching to HCG.
Fig. 5. Graph showing linear correlation between sum total of cross sectional area of 
      follicles and serum estradiol levels on the day switching to HCG.
Fig. 4. Correlation with maximum follicular di-
      ameter and ovulation in 88 cycles (.-
      pregnancy).
 which we measured it at the time of switching 
 to HCG, but we could not find a high cor-
 relation between them (r=0.3817) (Fig. 3). 
 2) Correlation with ovulation 
 After examining the correlation between mFD 
 and ovulation in 88 cycles, we found that the 
 minimum level of mFD at which ovulation 
 occurred was 15mm and ovulation occurred 
 in all cases where the follicular diameter was 
 more than 18mm (Fig. 4). 
3. Sum total of cross sectional areas of all fol-
 licles (FA) 
 1) Correlation with serum estradiol 
 The correlation coefficient between FA and 
 serum eatradiol levels in 88 cycles was 0.8099, 
 so we found a high correlation between them.
fig. 6. The relation between sum total of cross 
      sectional area of all follicles in bilateral 
      ovaries and ovulation or OHSS in 88 cycles 
      (• OHSS, OO severe OHSS, / pregnancy).
By using regression coefficients, FA 7.0cm2 
was equivalent to approximately 800 pg/ml 
of the serum estradiol levels (Fig. 5). 
2) Correlation between ovulation and OHSS 
The range of FA in 76 ovulatory cycles was 
1.6-20.2cm2. On the other hand, the range of 
FA was 1.7-7.3cm2 in 12 cycles in which there 
was no ovulation, and FA in 30 cycles in which 
OHSS occurred was 2.5-20.2cm2. Severe OHSS, 
among these 30 cycles of OHSS, occurred in 
6 cycles and the range of their FA was 7.2-
16.2cm2 (Fig. 6).
         DISCUSSION 
1) The mechanism of OHSS occurrence 
We think that prostaglandin (PG) and histamine 
are related to the occurrence of OHSS at the
time of HMG-HCG therapy. According to the 
reports by Pride et. al.", Chlorpheniramin 
(histamine-1 receptor blockade) and Pergonal 
were simultaneously administered to rabbits, 
and the weight of their ovaries, the quantity of 
ascites and the quantity of PG in ovaries were 
measured. Then they compared those weights, 
quantities and contents with a group of rabbits 
which were given only pergonal, and conclud-
ed that the direct effect of PG against OHSS 
occurrence is negligible, but PG is possibly con-
cerned with OHSS occurrence through vasoac-
tive substances such as histamine and so on. 
Now we see many reports that measurement of 
estrogen in urine and serum is useful to prevent 
OHSS occurrence. Therefore, we consider that 
estrogen is concerned in the mechanism of 
OHSS occurrence. Engel et. al." mention an 
effect of estrogen as pathogenesis of OHSS, and 
Schenker') describes it as follows : OHSS occur-
rence can not be explained by only estrogen, 
nor is estrogen a main factor of OHSS occur-
rence. But as a large quantity of estrogen ac-
celerates PG production, it is concerned in the 
mechanism of OHSS occurrence. 
To think of the mechanism of OHSS occurrence 
mentioned above, we suppose that excessive 
estrogen accelerates PG production, which in-
duce the secretion of vasoactive substances like 
histamine and so on, so that OHSS occurs by 
increased capillary permeability. 
2) Prediction of OHSS occurrence 
i) Comparison between assay of estrogen and 
USG 
 Too much estrogen is an indirect cause of 
OHSS, as has been stated. Therefore, if we 
measure the level of estradiol in urine and se-
rum and establish the critical level for OHSS 
occurrence, we can prevent OHSS. Judging from 
the results with our patiens, we can prevent 
severe OHSS, if we switch from HMG to HCG 
when the level is less than 800 pg/ml. However, 
the assay of estrogens entails cumbersome, 
timeconsuming procedures. Even if a rapid and 
simple method to measure estrogen is devel-
oped, it is difficult to judge each follicle's size 
(degree of maturity) from estrogen levels as a 
large number of follicles grow at the same time 
when using HMG therapy. 
The same problem is pointed out by Smith et.
al.'). On the other hand, USG is useful to es-
tablish when to induce ovulation (by changing 
from HMG to HCG) as each follicle's size can 
be determined by USG. Therefore, if USG 
makes it possible to predict OHSS, USG be-
comes a monitoring method combining both 
pervention of OHSS and induction of ovulation. 
Its clinical significance is quite big. 
ii) Maximum follicular diameter (mFD) 
 It is hard to estimate estorgen level from mFD, 
as the correlation between mFD and serum 
estradiol level is quite low. Therefore, mFD can 
hardly become an indicator for OHSS. However, 
when we switched from HMG to HCG at the 
time when mFD was larger than 18mm, we 
found ovulation in all cases, so that FD is quite 
useful as a parameter to decide when to induce 
ovulation by HCG. From the view point of mini-
mizing the number of ovulations and prevent-
ing OHSS, it would be advantageous to change 
to HCG at the time when follicular diameter 
reaches the minimum limit (mFD 15mm) at 
which it is possible to ovulate. But all mFD 
at the time, switching to HCG, were larger than 
19mm in pregnant cases. McNatty et. al." 
recently reported that only follicles of 18 to 
25mm had a granulosa cell complement con-
sistent with impending ovulation. However, 
they point out that when the diameter is smaller 
than 18mm or larger than 25mm, the number 
of granulosa cells decreases. Therefore, it is 
proper to change to HCG when FD is about 18-
19mm, in case of inducing ovulation for the 
purpose of conception. However, there exists 
a time lag of more than 24 hours between the 
time of switching to HCG and the time of 
ovulation. Therefore, mFD is supposed to be 
larger than 20mm at ovulation even though we 
change from HMG to HCG when mFD is 18mm. 
iii) Sum total of follicular cross sectional area 
(FA) 
 At the time when HMG was administered, 
serum estradiol level represents the sum total 
of estrogen which is secreted from many 
developed follicles, and the sum total of fol-
licular volume reflets serum estradiol level 
well'). So, if we measure the sum total of fol-
licular volume by USG, we can guess the serum 
estradiol level and it becomes a predictive para-
meter for the occurrence of OHSS. However,
as it is troublesome and also technically difficult 
to measure so many follicul's volumes by USG, 
it is hard to use this method daily in the clinics, 
so we substituted the follicular cross sectional 
area. It is supposed that the total of follicular 
cross sectional area (FA) and serum estradiol 
levels are strongly related, and FA reflects 
serum estradiol level well. Though moderate 
OHSS occurs when FA is less than 7.0cm2, no 
severe OHSS occurs and moderate OHSS is not 
a big problem clinically. Therefore, if we switch 
to HCG with the criteria that FA is less than 
7.0cm2 and mFD is larger than 18mm, we can 
certainly induce ovulation without severe OHSS. 
If we stop giving HCG without consideration 
for follicular diameter when FA is larger than 
7.0cm2, we can prevent severe OHSS occurrence. 
 Though 19 cases out of 76 ovulatory cycles 
(25%) did not satisfy these criteria, OHSS oc-
currence was not recognized. Therefore, if we 
use these criteria, it means that we would not 
give HCG to cases which would have probably 
been normal. This tells us that the appropriate 
effective dose of HMG easily induces OHSS, that 
is, HMG is an agent having a relatively small 
margin of safety between successful induction 
of ovulation and OHSS occurrence. This is a 
subject to be improved in the future. 
 Here we introduced the use of aum total of 
follicular cross sectional area by USG as an 
indicator for predicting the occurrence of OHSS 
and discussed its usefulness. Monitoring of 
follicular development by USG is easy and 
rapid, so that it will become an indispensable 
examination for induced ovulation by go-
nadotropin.
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